Other languages Astellas Pharma Inc. OTC Markets

Equities

ALPMY

US04623U1025

Market Closed - OTC Markets Other stock markets 03:59:59 2024-07-12 pm EDT			5-day change	1st Jan Change
10.46 ^USD	+1.26%		+4.39%	-12.10%

Jul. 02	Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer	CI
Jun. 03	US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer	Jul. 01
Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies	May. 21
Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor	May. 08
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	May. 02
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Apr. 30
MÄRKTE ASIEN/Freundlich - Yen lotet neue Tiefs aus	Apr. 26
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024	Apr. 25
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024	Apr. 25
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	Apr. 25
Astellas Pharma Inc. Announces Board and Committee Retirements	Apr. 25
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting	Apr. 23
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	Apr. 22
Japan Inc makes a renewed U.S. push as China fears mount	Apr. 17
Middle East Tensions Blunt Asian Stock Markets Excepting China	Apr. 15
MIDDAY BRIEFING - Unternehmen und Märkte	Apr. 15
MÄRKTE ASIEN/Börsen stecken Eskalation im Nahen Osten gut weg	Apr. 15
Aktien Asien/Pazifik: Eskalation im Nahen Osten drückt die Kurse - CSI legt zu	Apr. 15
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	Apr. 15
Japan's Nikkei sags as Iran attack, Wall Street sell-off sour sentiment	Apr. 15
Japan's Nikkei drops 1% as Iran attack, Wall Street sell-off fuel risk aversion	Apr. 14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Astellas Pharma Inc. OTC Markets

Equities

ALPMY

US04623U1025

Other languages

Filters